Suven Life Sciences has announced its un-audited financial results for the quarter ended December 31, 2013. For the third quarter ended December 2013, the company has seen a growth in revenue of Rs 1203 million, a growth in profit after tax (PAT) of Rs 364 million and a growth in earnings before interest, taxes, depreciation, and amortization (EBITDA)of Rs 557 million.
For nine months ending December 2013, the company has posted a growth in revenue of Rs 3836 million, growth in PAT of Rs 1118 million and growth in EBITDA of Rs 1734 million.
EP News Bureau – Mumbai
- Advertisement -
